# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

15. **Posluma**: On May 25, 2023, Posluma, with the active ingredient flotufolastat F 18, was approved for use with positron emission tomography imaging in certain patients with prostate cancer.

16. **Fruzaqla**: Fruzaqla, containing fruquintinib, was approved on November 8, 2023, for the treatment of refractory, metastatic colorectal cancer.

17. **Exxua**: Approved on September 22, 2023, Exxua, with the active ingredient gepirone, is indicated for the treatment of major depressive disorder.

18. **Columvi**: Columvi, containing glofitamab-gxbm, was approved on June 15, 2023, for the treatment of diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy.

19. **Fabhalta**: On December 5, 2023, Fabhalta, with the active ingredient iptacopan, was approved for the treatment of paroxysmal nocturnal hemoglobinuria.

20. **Leqembi**: Approved on January 6, 2023, Leqembi, containing lecanemab-irmb, is indicated for the treatment of Alzheimerâ€™s disease.

21. **Joenja**: Joenja, with the active ingredient leniolisib, was approved on March 24, 2023, for the treatment of activated phosphoinositide 3-kinase delta syndromes.

22. **Xdemvy**: Approved on July 25, 2023, Xdemvy, containing lotilaner, is used for the treatment of Demodex blepharitis.

23. **Omvoh**: Omvoh, with the active ingredient mirikizumab-mrkz, was approved on October 26, 2023, for the treatment of ulcerative colitis.
